Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Blopress Excluded from Generic Share Calculation until September
June 23, 2014
- Broad Perspective Important for Vaccination Policy: CDC Official
June 23, 2014
- LDP OKs Revised Version of Draft Economic, Fiscal Policy Guidelines
June 20, 2014
- First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
- PAFSC’s Second Committee to Discuss Approval for IFN-Free Hepatitis C Treatments on June 26
June 19, 2014
- Drug Price Settlement Rate for March 2014 at 98.4%: MHLW
June 19, 2014
- LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
- MHLW on Tap to Launch Expedited Drug Review System in 2015
June 18, 2014
- Govt Weighs Applying Mixed Care Scheme to Low Cost-Effective Drugs: Draft Growth Strategy
June 17, 2014
- PMDA Reviewing Osteoporosis Treatment Forteo for Risk of Shock, Anaphylaxis
June 17, 2014
- “Annual” NHI Price Revision Erased from Gov’t Draft Policy Blueprint
June 16, 2014
- Regulatory Reform Proposal Including Expansion of Mixed Care Use Submitted to Prime Minister
June 16, 2014
- LDP Members with Vested Interests Slam Annual NHI Price Revision
June 12, 2014
- MHLW Panel OKs Draft Report on Medical Database Project, but Further Discussion Needed for Drug Makers’ Usage
June 12, 2014
- Expansion of “Mixed Care” Cited in Outline for New Growth Strategy
June 12, 2014
- MHLW to Seek Opinions on Abe’s New Mixed Care Plan from Advisory Panels
June 11, 2014
- PM Abe Vows to Forge New System to Accelerate Mixed Care
June 11, 2014
- Health Minister Still Cautious about Annual Drug Price Revision
June 11, 2014
- Ex-Novartis Employee Nabbed over Diovan Data Tampering: Reports
June 11, 2014
- Govt Tilting Toward Etching Annual NHI Price Revision in Fiscal Blueprint
June 10, 2014
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…